Remove FDA Approval Remove Hormones Remove Life Science
article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

The therapy is approved to be used in combination with glucocorticoid replacement therapies (steroids) to control androgen levels in adults and pediatric patients four years of age and older with classic CAH. Currently, the standard treatment for CAH involves glucocorticoids, which replace cortisol and help regulate hormone levels.

Genetics 116
article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves New Type 2 Diabetes Injection Mounjaro + US Reports First Case of Monkeypox – Xtalks Life Science Podcast Ep. 62

XTalks

In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP).

article thumbnail

Sanofi Wins FDA Nod for Merilog, First Rapid-Acting Insulin Biosimilar

XTalks

Biosimilars are biological products highly similar to an already FDA-approved reference product, with no clinically meaningful differences in terms of safety, purity and potency. Insulin, a hormone produced by the pancreas, allows glucose to enter cells for energy. Approximately 8.4

Insulin 59
article thumbnail

Xtalks Speaks with Astellas Pharma’s VP & Head of BioPharma Development Marci English About Menopause Drug Approval – Xtalks Life Science Podcast Ep. 116

XTalks

This episode features an interview with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma, about the recent FDA approval of the company’s drug Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause.

article thumbnail

Aardvark Therapeutics IPO Sets Sights on Satiating Hyperphagia and Extreme Hunger

XTalks

In the gut, these receptors prompt the release of hormones such as cholecystokinin and GLP-1, which together signal satiety. This approach aims to combine TAS2R activation with enhanced incretin hormone modulation, potentially offering a more robust treatment for obesity and related conditions.

article thumbnail

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder

XTalks

Amvuttra’s FDA approval is based on positive data from the global, randomized, open-label, multicenter HELIOS-A Phase III study from a period of nine months. TTR is made in the liver and is involved in carrying the thyroid hormone thyroxine (T4) and retinol (vitamin A) to the liver.